Search
Search

연구성과물 검색 타이틀 이미지

HOME ICON HOME > Search by Achievements Type > Reports View

Reports Detailed Information

https://www.krm.or.kr/krmts/link.html?dbGubun=SD&m201_id=10011499&local_id=10018409
Effects of epigallocatechin-3-gallate on high glucose-induced glomerular epithelial cell damage
Reports NRF is supported by Research Projects( Effects of epigallocatechin-3-gallate on high glucose-induced glomerular epithelial cell damage | 2005 Year 신청요강 다운로드 PDF다운로드 | 박성준(전남대학교) ) data is submitted to the NRF Project Results
Researcher who has been awarded a research grant by Humanities and Social Studies Support Program of NRF has to submit an end product within 6 months(* depend on the form of business)
사업별 신청요강보기
  • Researchers have entered the information directly to the NRF of Korea research support system
Project Number C00040
Year(selected) 2005 Year
the present condition of Project 종료
State of proposition 재단승인
Completion Date 2008년 01월 08일
Year type 결과보고
Year(final report) 2008년
Research result report
  • Abstract
  • This study was designed to investigate whether EGCG plays a cytoprotective role in glomerular epithelial cells (GECs) under high glucose conditions. MTT assays showed that treatment with a high concentration of glucose (30 mM) significantly increased apoptosis among cultured GECs as compared with that observed for a normal glucose concentration (5 mM). Pretreatment with EGCG (1-100 μM) significantly increased cell viability under the high glucose condition in a dose-dependent manner. DNA fragments was induced by glucose at 30 mM for 24 hr, whereas pretreatment for 2 hr with EGCG (1-100 μM) conferred significant protection against this glucose-induced DNA fragmentation. Moreover, DAPI staining assays showed that treatment with a high concentration of glucose (30 mM) increased DNA fragmentation / condensation in GECs as compared with that observed for a normal glucose concentration (5 mM). Pretreatment of GECs with EGCG (1-100 μM) significantly increased cell viability under the high glucose condition in a dose-dependent manner. Mechanism of reactive oxygen species (ROS)-mediated apoptosis induced by glucose (30 mM) was examined. It was found that glucose at 30 mM rapidly stimulated the generation of intracellular ROS, whereas pretreatment with EGCG (1-100 μM) significantly decreased generation of ROS under the high glucose condition in a dose-dependent manner. As well as, treatment of high glucose (30 mM) increased lipid peroxidation (LPO) and decreased glutathione (GSH) in GECs. Pretreatment with 100 μM EGCG attenuated the increase of LPO and restored the activity of GSH. These results suggest that high glucose-induced oxidative stress is a critical role in GECs apoptosis. Next, the role of EGCG in relation of p38 MAPK and ERK1/2 was investigated in GECs at high glucose conditions. It was found that glucose at 30 mM rapidly increased the phosphorylations of p38 MAPK and ERK1/2, whereas pretreatment with EGCG (1-100 μM) significantly prevented these phosphorylations in glucose concentration at 30 mM in a dose-dependent manner. Expression of apoptotic factors revealed that EGCG prevented the expression of the pro-apoptotic factors, such as Bad, caspase-3 and -9 by glucose at 30 mM, whereas EGCG pretreatment increased the expressions the anti-apoptotic factors, such as Bcl-2 and Bcl-xL in GECs. These data indicate that EGCG protects against apoptotic cell death by stimulating phospho-p38 MAPK and phospho-ERK1/2 and up-regulation of antiapoptotic factors, the other side down-regulation of proapoptotic factors in high glucose-conditioned GECs. Next, it was investigated the role of transforming growth factor-beta1 (TGF-β1), protein kinase C (PKC) α/βII and nuclear factor-kappaB (NF-κB) in GECs against high glucose injury. Glucose at 30 mM rapidly increased the expressions of mRNA and protein of TGF-β1, the other side, pretreatment with EGCG (1-100 μM) significantly prevented expressions of TGF-β1 in glucose concentration at 30 mM in a dose-dependent manner. In addition, EGCG (100 μM) inhibited phospho-PKC α/βII activation caused by glucose at 30 mM and pretreatment with EGCG (1-100 μM) significantly decreased the expression of transcriptional activity of NF-κB induced by glucose at 30 mM in a dose-dependent manner. These data indicate that 1) the protective mechanism of EGCG against high glucose-induced apoptotic cell death includes stimulation of phospho-p38 MAPK and phospho-ERK1/2 and modulation of apoptosis-regulating factors, 2) EGCG prevents high glucose-induced expression of TGF-β1, phospho-PKC α/βII and NF-κB.

  • Research result and Utilization method
  • When cells were subjected to glucose at 30 mM for 24 hr, it was observed early apoptotic changes. MTT assays showed that treatment with a high concentration of glucose (30 mM) significantly increased apoptosis among cultured GECs as compared with that observed for a normal glucose concentration (5 mM). Pretreatment with EGCG (1-100 μM) significantly increased cell viability under the high glucose condition in a dose-dependent manner. DNA fragments was induced by glucose at 30 mM for 24 hr, whereas pretreatment for 2 hr with EGCG (1-100 μM) conferred significant protection against this glucose-induced DNA fragmentation. Moreover, DAPI staining assays showed that treatment with a high concentration of glucose (30 mM) increased DNA fragmentation / condensation in GECs as compared with that observed for a normal glucose concentration (5 mM). Pretreatment of GECs with EGCG (1-100 μM) significantly increased cell viability under the high glucose condition in a dose-dependent manner. Mechanism of reactive oxygen species (ROS)-mediated apoptosis induced by glucose (30 mM) was examined. It was found that glucose at 30 mM rapidly stimulated the generation of intracellular ROS, whereas pretreatment with EGCG (1-100 μM) significantly decreased generation of ROS under the high glucose condition in a dose-dependent manner. As well as, treatment of high glucose (30 mM) increased lipid peroxidation (LPO) and decreased glutathione (GSH) in GECs. Pretreatment with 100 μM EGCG attenuated the increase of LPO and restored the activity of GSH. These results suggest that high glucose-induced oxidative stress is a critical role in GECs apoptosis. Next, the role of EGCG in relation of p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) was investigated in GECs at high glucose conditions. It was found that glucose at 30 mM rapidly increased the phosphorylations of p38 MAPK and ERK1/2, whereas pretreatment with EGCG (1-100 μM) significantly prevented these phosphorylations in glucose concentration at 30 mM in a dose-dependent manner. Subsequently, it was examined the role of EGCG in the expression of apoptotic factors. Expression of apoptotic factors revealed that EGCG prevented the expression of the pro-apoptotic factors, such as Bad, caspase-3 and -9 by glucose at 30 mM, whereas EGCG pretreatment increased the expressions the anti-apoptotic factors, such as Bcl-2 and Bcl-xL in GECs. These data indicate that EGCG protects against apoptotic cell death by stimulating phospho-p38 MAPK and phospho-ERK1/2 and up-regulation of antiapoptotic factors, the other side down-regulation of proapoptotic factors in high glucose-conditioned GECs. Next, it was investigated the role of transforming growth factor-beta1 (TGF-β1), protein kinase C (PKC) α/βII and nuclear factor-kappaB (NF-κB) in GECs against high glucose injury. Glucose at 30 mM rapidly increased the expressions of mRNA and protein of TGF-β1, the other side, pretreatment with EGCG (1-100 μM) significantly prevented expressions of TGF-β1 in glucose concentration at 30 mM in a dose-dependent manner. In addition, EGCG (100 μM) inhibited phospho-PKC α/βII activation caused by glucose at 30 mM and pretreatment with EGCG (1-100 μM) significantly decreased the expression of transcriptional activity of NF-κB induced by glucose at 30 mM in a dose-dependent manner. These data indicate that 1) the protective mechanism of EGCG against high glucose-induced apoptotic cell death includes stimulation of phospho-p38 MAPK and phospho-ERK1/2 and modulation of apoptosis-regulating factors, 2) EGCG prevents high glucose-induced expression of TGF-β1, phospho-PKC α/βII and NF-κB. Thus, EGCG could be a useful factor modulating the GECs injury by high glucose. Furthermore, EGCG might be a useful candidate for controlling diabetic nephropathy effectively.
  • Index terms
  • glomerular epithelial cells, EGCG, ROS, MAPK, Apoptosis, TGF-β1, NF-κB
  • List of digital content of this reports
데이터를 로딩중 입니다.
  • This document, it is necessary to display the original author and you do not have permission
    to use copyrighted material for-profit
  • In addition , it does not allow the change or secondary writings of work
데이터 이용 만족도
자료이용후 의견
입력
트위터 페이스북
NRF Daejeon
(34113) 201, Gajeong-ro, Yuseong-gu, Daejeon, Korea
Tel: 82-42-869-6114 / Fax: 82-42-869-6777
NRF Seoul
(06792) 25, Heonreung-ro, Seocho-gu, Seoul, Korea
Tel: 82-2-3460-5500 / Fax: 82-2-3460-5759
KRM Help Center
Tel : 042-710-4360
E-mail : krmcenter@nrf.re.kr / Fax : 042-861-4380